Objectives: Analysis of participation in drug costs by seniors in the Czech Republic in connection with seniors' access to pharmacotherapy. Materials and methods: Quota-sampled guided interview with 450 respondents visiting pharmacy; ratio of men and women approximately 1:2; age over 60 years; 3 regions of the Czech Republic.
INTRODUCTION
Pharmaceutical expenditures represent continually substantial part of resources spent on health care in the Czech Republic. From 1990 till 2004 total pharmaceutical expenditures (TPhE) amounted to 25 to 28% of total health expenditures (THE) (1, 2) . In this respect, the Czech Republic significantly outruns an average of West European countries, where TPhE usually amount to 14% of THE (3, 4) . More than 20% of THE is usually spent on pharmaceuticals in other post-socialistic countries (Bulgaria, former Jugoslavia) (5) .
In 2004, THE amounted to 198 Mld. CZK (1 US$ = 22.4 CZK or 1 € = 27.8 CZK), which was 7.16% of Gross Domestic Product (GDP). Public and private resources covered 91.2% and 8.8%, respectively.
Private payments occur mainly in the category of medicines in the Czech Republic. Total pharmaceutical expenditures were 52.5 Mld. CZK in 2003 and insurance funds (i.e. public resources) covered 36 Mld. CZK from this amount (6) . The rest was covered by payments for over-the-counter (OTC, i.e. non-prescription)
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As to the structure of those expenditures in the society, in an average household a person spent in 2004 on health and pharmaceuticals 144 and 117 CZK (i.e. 1.52% and 1.24%) of his/her income, respectively. In the households of seniors a person spent in 2004 212 and 161 CZK (i.e. 2.58% and 1.61%), respectively (7) .
The Act on Public Health Insurance (8) clusters all reimbursed medicines into 300 groups based upon their therapeutic classification and administration route and it explicitly specifies that in each group at least one medicinal product shall be fully reimbursed. In this way, there should always be a fully reimbursed alternative to choose by the physician and the patient.
But the definition of groups appears problematic and it seems to be not sufficient for all medical situations. There are no official incentives for prescribing doctors to choose fully reimbursed or cheaper or generic products in the Czech Republic. Generic substitution in pharmacy has not been introduced.
In the first quarter 2004, there were 8,845 pharmaceutical products on the market in the Czech Republic (9) . Only 21.71% of them were defined as fully reimbursed. However, the real number of fully reimbursed products on the market might be higher since this methodology operates only with the maximum prices set by Ministry of Finance.
In 2004 each citizen of the Czech Republic received 9.23 physician's prescriptions for pharmaceuticals (10) and the average co-payment per prescription was 54 CZK. Total consumption of pharmaceuticals amounted to 329 Mil. packs.
Unfortunately, there is no publicly available information concerning structure of pharmaceutical consumption and expenditures of different age or social groups in the Czech Republic. The only information available is on total health expenditures per capita (18,000 CZK and 1,302 US$ PPP in 2003, respectively) (6, 11) and per insured person in different age categories (with an average of 14,600 CZK in 2004) (10) . Health expenditures per insured person significantly increase in patients aged over 55 years. From 60 years of age, total health expenditures amount to more than double of the average.
Our study aims to describe seniors' participation in expenditures on prescribed and OTC pharmaceuticals in the Czech Republic. Further, it focuses on influence of these costs on seniors' access to pharmacotherapy.
MATERIALS AND METHODS
Guided interview was chosen as a method of investigation. Our three inquirers had a schema available with 22 questions. Several questions were closed (basic demographic data) and in the other questions respondents were asked to choose one of alternative answers.
Inclusion criteria were: visit at a pharmacy for prescribed pharmaceuticals, age 60 and older. Respondents were included into sample by quota sampling, i.e. until desired number of respondents was reached. Men and women were included separately so the final ratio in the sample reached 1:2 (corresponding to distribution of sex in these age categories).
Main exclusion criterion was a stay in pensioners' home, where personnel dispense medication. Further, persons, who were not willing or able to answer questions about their income and/or spending, were excluded from the sample.
Respondents were searched for in three regions of the Czech Republic with different socio-economic structure. 
RESULTS
Set of respondents amounted to 450 persons aged over 60 years, who visited pharmacy to obtain prescribed medication. Men : Number of respondents using only fully reimbursed pharmaceuticals was 117 (i.e. 26%). Ratio of fully reimbursed products used by respondents was 44.30%.
Average respondents spent on medicines 123 CZK in the last four weeks, i.e. 1.5% of the official state average income. There were respondents, about 10% of them, searching for the level of co-payment in several pharmacies and 8.6% of respondents, who had to refuse dispensation of medicines due to co-payment.
DISCUSSION
According to official statistic data seniors spend about 2.5% of their income on health, with pharmaceuticals share of about 1.5% (7) . This number doesn't seem too high. But our results show that more than 55% of respondents may not reach the official average income. Further, there were 26% of respondents in our research group, who used only fully reimbursed medicines. Intentionally, we didn't include seniors who didn't consume any medicines. So those who participated on cost of their medicines spent in average 209 CZK i.e. 2.5% of their income only on medicines. Maximal amount paid during last four weeks was 3,000 CZK by a respondent to whom 16 different medicinal products were prescribed. This was a great exception and was excluded from statistical analysis.
Results of our study may vary from official data mainly due to excluding respondents, who didn't use any medicines and persons who were not able to take care about obtaining medications themselves anymore. Respondents, who were not willing to or not able to answer questions about their income and spending on medication, were excluded, too.
Further, we understand the limitations of sociological methods we used. We worked with respondents 60 years old and older so possible deviation may occur due to worse memory of exact spending and possible rounding.
Strong points of our study are that interviews were carried out in pharmacy and so in most cases it was possible to identify the exact medicinal products used by respondents and identify those products by a registration code. Pharmacy setting enabled to eliminate doubling of spending when more packs of a product were prescribed, too. Accordingly expenditures correspond in large scale to a real four-week consumption of medication.
Some respondents (about 10%) searched for level of co-payments in different pharmacies to achieve the lowest participation. However, in deeper analysis we found out, that those respondents lived mainly in the capital, were they could visit many more pharmacies.
Further, our study shows great differences in level of co-payment of concrete medicinal product depending mainly on the size of the city or town and on the size and type of the pharmacy the respondents visited. Pharmacies with great returns may lower their part of trade margin and in this way lower possible co-payment to attract more customers.
There were respondents in our research group (about 8.6%), who were forced to reject the dispensation of their medicines due to the level of co-payment. The situation occurred mainly in respondents using more than one medicinal product and in some respondents, to whom medication for more months was prescribed.
Seniors are particularly vulnerable population concerning quality of life, defined as complex concept of person's physical health, psychological state, level of independence and social relationship (13) . Even slight changes of health state may result in worsening of social status and vice versa. Impaired social or financial situation usually has a great impact on health in this population group.
Our interviewers noted that the number of respondents rejecting the dispensation due to co-payment fluctuated during the study period and they suggest that it may depend on the length of time before or after they receive the income.
In our opinion, situation might be improved by introducing some instrument setting up the limit for individual participation for example in 12-month period as in Sweden (14) or excluding chronic and/or senior patients from financial participation, as it is in some other countries (15) .
Our study demonstrates that there may be patients who may fail to gain access to medication due to co-payment. The financial participation on health care costs is generally low in the Czech Republic (8.8 % of total health expenditures) but there were differences in co-payment levels in patients ranging from 1 CZK to thousands CZK.
In our study co-payments were lower in very small communities, which may be due to better communication between physicians and patients or physicians and pharmacists and in the capital (which is most probably due to competition of pharmacies).
In the near future, private spending in health care might rise in the Czech Republic. The amendment of the Act on public health insurance in force from 2008 (16) introduces a fee for visiting a physician and fees for prescribed medicinal products in value of 30 CZK each. To protect the patients from excessive costs, the amendment introduces a limit of co-payment in value of 5,000 CZK in one year.
Chronic medication is usually prescribed in three or six month interval. Respondents in our study used approx. 3.70 medicines. Their co-payment would increase due to fees upon approx. 111 CZK (123 or 105 CZK instead of 86 CZK) in four weeks. This would represent an increase of 140 or 120%.
However, there is a need for future studies to analyse the exact impact of this new legislation on private spending in the Czech Republic.
In our study, we found a critical ethical problem in different levels of co-payment for concrete product. Although the range of all co-payments was within legal limits, differences show a possible adverse selection in less economically stable regions. In this way, citizens of the Czech Republic may fail to receive the health care under the same terms as declared by the constitution.
